Radiosensitization by the mTOR inhibitor RAD001 involves the induction of autophagy in two cancer cell lines

被引：0
|
作者：
Bischoff, Pierre L. [1 ]
Altmeyer, Anais [1 ]
Josset, Elodie [1 ]
Denis, Jean -Marc [2 ]
Gueulette, John [2 ]
Slabbert, Jakobus P. [3 ]
Noel, Georges [1 ]
机构：
[1] Univ Strasbourg, Ctr Paul Strauss, EA 3430, Strasbourg, France
[2] Catholic Univ Louvain, MIRO, B-1200 Brussels, Belgium
[3] iThemba LABS, Somerset West, South Africa
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/1538-7445.AM2012-1466
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1466
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Activity of mTOR-Inhibitor Rad001 (everolimus) in differentiated and anaplastic thyroid cancer cell lines
    Behlendorf, T.
    Voigt, W.
    Mueller, T.
    Jordan, K.
    Arnold, D.
    Schmoll, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [2] Effects of mTOR Inhibitor Everolimus (RAD001) on Bladder Cancer Cells
    Chiong, Edmund
    Lee, I-Ling
    Dadbin, Ali
    Sabichi, Anita L.
    Harris, Loleta
    Urbauer, Diana
    McConkey, David J.
    Dickstein, Rian J.
    Cheng, Tiewei
    Grossman, H. Barton
    CLINICAL CANCER RESEARCH, 2011, 17 (09) : 2863 - 2873
  • [3] EFFECTS OF MTOR INHIBITOR EVEROLIMUS (RAD001) ON BLADDER CANCER CELLS
    Chiong, Edmund
    Lee, I-Ling
    Dadbin, Ali
    Sabichi, Anita L.
    McConkey, David J.
    Grossman, H. Barton
    JOURNAL OF UROLOGY, 2009, 181 (04): : 406 - 406
  • [4] The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines
    Brigette B. Y. Ma
    Vivian W. Y. Lui
    Edwin P. Hui
    Cecilia P. Y. Lau
    Kakiu Ho
    Margaret H. L. Ng
    S. H. Cheng
    Sai-Wah Tsao
    Anthony T. C. Chan
    Investigational New Drugs, 2010, 28 : 413 - 420
  • [5] The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines
    Ma, Brigette B. Y.
    Lui, Vivian W. Y.
    Hui, Edwin P.
    Lau, Cecilia P. Y.
    Ho, Kakiu
    Ng, Margaret H. L.
    Cheng, S. H.
    Tsao, Sai-Wah
    Chan, Anthony T. C.
    INVESTIGATIONAL NEW DRUGS, 2010, 28 (04) : 413 - 420
  • [6] Role of the Novel mTOR Inhibitor RAD001 (Everolimus) in Anaplastic Thyroid Cancer
    Papewalis, C.
    Wuttke, M.
    Schinner, S.
    Willenberg, H. S.
    Baran, A. M.
    Scherbaum, W. A.
    Schott, M.
    HORMONE AND METABOLIC RESEARCH, 2009, 41 (10) : 752 - 756
  • [7] Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma
    Oudard, Stephane
    Medioni, Jacques
    Aylllon, Jorge
    Barrascourt, Eduardo
    Elaidi, Reza-Thierry
    Balcaceres, Jose
    Scotte, Florian
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (06) : 705 - 717
  • [8] Effects of an mTOR Inhibitor RAD001 on Human Breast Cancer Stem Cells In Vitro
    Zhang, J.
    Zhang, X. B.
    Liu, J. J.
    Mao, Q. X.
    Ma, Y.
    Zhang, S.
    CANCER RESEARCH, 2010, 70
  • [9] mTOR Inhibitor RAD001 Promotes Metastasis in a Rat Model of Pancreatic Neuroendocrine Cancer
    Pool, Stefan E.
    Bison, Sander
    Koelewijn, Stuart J.
    van der Graaf, Linda M.
    Melis, Marleen
    Krenning, Eric P.
    de Jong, Marion
    CANCER RESEARCH, 2013, 73 (01) : 12 - 18
  • [10] Activity of dual PI3K/mTOR inhibitor, NVP-BEZ235, and mTOR inhibitor, RAD001 (everolimus), in endometrial cancer cell lines.
    Shoji, K.
    Oda, K.
    Nakagawa, S.
    Ikeda, Y.
    Kuramoto, H.
    Nishida, N.
    Kawana, K.
    Yano, T.
    Kozuma, S.
    Taketani, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345